While a driver mutation such as oncogenic KRAS directly alters metabolic pathways, cancers that successfully grow and evade the immune system undergo selective pressures from hypoxia, limited precursor availability, and secondary stimulation of pro- and anti-inflammatory responses by metabolic by-products (4–8). This evidence concerns the gene KRAS and cancer.